UK’s first oral treatment for postnatal depression approved by MHRA

Zuranolone has become the first oral treatment for postnatal depression (PND) to be approved for the UK by the Medicines and Healthcare products Regulatory Agency (MHRA). The drug, which carries the brand name Zurzuvae, can be used for the treatment of moderate to severe PND in adults following childbirth. Zuranolone is supplied as capsules and The post UK’s first oral treatment for postnatal depression approved by MHRA appeared first on Pulse Today.